

**Supplementary material****Supplementary Table S1: Radiologic criteria for response assessment**

	<b>RECIST 1.1</b>	<b>EASL</b>	<b>mRECIST</b>
<b>COMPLETE RESPONSE (CR)</b>	Disappearance of all targets lesions (up to two measurable liver lesions).	Disappearance of any intratumoral arterial enhancement in all measurable arterially-enhancing liver lesions.	Disappearance of any intratumoral arterial enhancement in all target lesions (up to two measurable liver lesions).
<b>PARTIAL RESPONSE (PR)</b>	At least a 30% decrease in the sum of the greatest unidimensional diameters of target lesions, taking as reference the baseline sum of the diameters of target lesions.	At least a 50% decrease in the sum of the product of bidimensional diameters of viable (enhancement in the arterial phase) target lesions, taking as reference the baseline sum of the diameters of the targets lesions.	At least a 30% decrease in the sum of unidimensional diameters of viable (enhancement in the arterial phase) target lesions, taking as reference the baseline sum of the diameters of the targets lesions.
<b>STABLE DISEASE (SD)</b>	Any cases that do not qualify for either partial response or progressive disease	Any cases that do not qualify for either partial response or progressive disease.	Any cases that do not qualify for either partial response or progressive disease.

<b>PROGRESSIVE DISEASE (PD)</b>	An increase of at least 20% in the sum of the diameters of target lesions, taking as reference the smallest sum of the diameters of target lesions recorded since treatment started.	An increase of at least 25% in the sum of the diameters of viable target lesions recorded since treatment started.	An increase of at least 20% in the sum of the diameters of the viable (enhancing) target lesions, taking as reference the smallest sum of the diameters of viable target lesions recorded since treatment started.
-------------------------------------	--	--	--

---